Doublet Versus Triplet Therapy in High-volume Metastatic Hormone-sensitive Prostate Cancer Patients with Bone Metastases: Results from the ARON-3 Study
Doublet Versus Triplet Therapy in High-volume Metastatic Hormone-sensitive Prostate Cancer Patients with Bone Metastases: Results from the ARON-3 Study. // European Urology Oncology. – URL: https://www.sciencedirect.com/science/article/pii/S2588931126001380?dgcid=rss_sd_all
Doublet Versus Triplet Therapy in High-volume Metastatic Hormone-sensitive Prostate Cancer Patients with Bone Metastases: Results from the ARON-3 Study. European Urology Oncology. https://www.sciencedirect.com/science/article/pii/S2588931126001380?dgcid=rss_sd_all
“Doublet Versus Triplet Therapy in High-volume Metastatic Hormone-sensitive Prostate Cancer Patients with Bone Metastases: Results from the ARON-3 Study.” European Urology Oncology.
@article{article118622,
title = {Doublet Versus Triplet Therapy in High-volume Metastatic Hormone-sensitive Prostate Cancer Patients with Bone Metastases: Results from the ARON-3 Study},
journal = {European Urology Oncology},
url = {https://www.sciencedirect.com/science/article/pii/S2588931126001380?dgcid=rss_sd_all}
}
Objective To assess prostate‐specific antigen (PSA) testing according to income, age, and region of residence in Sweden. Patients and Methods We conducted a nationwide, population‐based open cohort study of men aged 40–90 years in...